Tags

Type your tag names separated by a space and hit enter

Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons.
Clin Biochem. 2007 Sep; 40(13-14):964-8.CB

Abstract

OBJECTIVES

Lifestyle changes with increased physical activity and balanced energy intake are recognized as the principal interventions in obesity and insulin resistance. Only few prospective studies, however, have so far addressed the potential role of routine biochemical markers of insulin sensitivity in the monitoring of respective interventions.

DESIGN AND METHODS

Fasting insulin and glucose was measured in 33 obese individuals undergoing a lifestyle modification program (MOBILIS) at baseline and after 1 year. The HOMA-IR index (homeostasis model of insulin resistance) was calculated as [fasting serum glucose*fasting serum insulin/22.5], with lower values indicating a higher degree of insulin sensitivity.

RESULTS

While the median body mass index (BMI) and waist circumference decreased by 10% and 11%, respectively, the HOMA-IR index decreased in an over-proportional manner by 45% within 1 year (BMI baseline, median 35.7, interquartile range (IQR) 33.7-37.7; after 1 year, median 32.2, IQR 29.6-35.1. HOMA-IR baseline, median 2.9, IQR 1.5-4.6; after 1 year 1.6, IQR 0.9-2.7). In contrast to HOMA-IR and fasting serum insulin, no significant changes in fasting serum glucose were observed. Baseline and post-intervention HOMA-IR showed a high degree of inter-individual variation with eight individuals maintaining high HOMA-IR values despite weight loss after 1 year of intervention.

CONCLUSIONS

Individual changes in the carbohydrate metabolism achieved by a lifestyle intervention program were displayed by fasting serum insulin concentrations and the HOMA-IR but not by fasting glucose measurement alone. Therefore, assessment of the HOMA-IR may help to individualize lifestyle interventions in obesity and to objectify improvements in insulin sensitivity after therapeutic lifestyle changes.

Authors+Show Affiliations

Institute of Clinical Chemistry, Hospital of the University of Munich, Marchioninistr. 15, D-81377 Munich, Germany. Michael.Vogeser@med.uni-muenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17583689

Citation

Vogeser, Michael, et al. "Fasting Serum Insulin and the Homeostasis Model of Insulin Resistance (HOMA-IR) in the Monitoring of Lifestyle Interventions in Obese Persons." Clinical Biochemistry, vol. 40, no. 13-14, 2007, pp. 964-8.
Vogeser M, König D, Frey I, et al. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem. 2007;40(13-14):964-8.
Vogeser, M., König, D., Frey, I., Predel, H. G., Parhofer, K. G., & Berg, A. (2007). Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clinical Biochemistry, 40(13-14), 964-8.
Vogeser M, et al. Fasting Serum Insulin and the Homeostasis Model of Insulin Resistance (HOMA-IR) in the Monitoring of Lifestyle Interventions in Obese Persons. Clin Biochem. 2007;40(13-14):964-8. PubMed PMID: 17583689.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. AU - Vogeser,Michael, AU - König,Daniel, AU - Frey,Ingrid, AU - Predel,Hans-Georg, AU - Parhofer,Klaus Georg, AU - Berg,Aloys, Y1 - 2007/06/02/ PY - 2006/07/03/received PY - 2007/04/27/revised PY - 2007/05/07/accepted PY - 2007/6/23/pubmed PY - 2007/11/6/medline PY - 2007/6/23/entrez SP - 964 EP - 8 JF - Clinical biochemistry JO - Clin. Biochem. VL - 40 IS - 13-14 N2 - OBJECTIVES: Lifestyle changes with increased physical activity and balanced energy intake are recognized as the principal interventions in obesity and insulin resistance. Only few prospective studies, however, have so far addressed the potential role of routine biochemical markers of insulin sensitivity in the monitoring of respective interventions. DESIGN AND METHODS: Fasting insulin and glucose was measured in 33 obese individuals undergoing a lifestyle modification program (MOBILIS) at baseline and after 1 year. The HOMA-IR index (homeostasis model of insulin resistance) was calculated as [fasting serum glucose*fasting serum insulin/22.5], with lower values indicating a higher degree of insulin sensitivity. RESULTS: While the median body mass index (BMI) and waist circumference decreased by 10% and 11%, respectively, the HOMA-IR index decreased in an over-proportional manner by 45% within 1 year (BMI baseline, median 35.7, interquartile range (IQR) 33.7-37.7; after 1 year, median 32.2, IQR 29.6-35.1. HOMA-IR baseline, median 2.9, IQR 1.5-4.6; after 1 year 1.6, IQR 0.9-2.7). In contrast to HOMA-IR and fasting serum insulin, no significant changes in fasting serum glucose were observed. Baseline and post-intervention HOMA-IR showed a high degree of inter-individual variation with eight individuals maintaining high HOMA-IR values despite weight loss after 1 year of intervention. CONCLUSIONS: Individual changes in the carbohydrate metabolism achieved by a lifestyle intervention program were displayed by fasting serum insulin concentrations and the HOMA-IR but not by fasting glucose measurement alone. Therefore, assessment of the HOMA-IR may help to individualize lifestyle interventions in obesity and to objectify improvements in insulin sensitivity after therapeutic lifestyle changes. SN - 0009-9120 UR - https://www.unboundmedicine.com/medline/citation/17583689/Fasting_serum_insulin_and_the_homeostasis_model_of_insulin_resistance__HOMA_IR__in_the_monitoring_of_lifestyle_interventions_in_obese_persons_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-9120(07)00207-X DB - PRIME DP - Unbound Medicine ER -